Investor Presentation Full Year 2021
41
Investor presentation Full year 2021
Novo Nordisk has a strong leadership position within the
growing diabetes market
Global diabetes market by treatment class¹
Novo Nordisk remains global diabetes
value market leader
Novo Nordisk market share and
share of growth
DKK billion
300
200
100
Market CAGR²: 8.7%
30%
CAGR: 0.4%
CAGR: 17.7%
20%
CAGR: 24.9%
10%
CAGR: (3.2%)
60%
30%
40%
20%
Novo NordiskⓇ
39%
30%
0
0%
0%
Nov
Nov
Nov
15FY
16FY
17FY
18FY
19FY
20FY
2011
2021
2018
Nov
2021
Insulin GLP-1
SGLT-2
DPP-4
Novo Nordisk
Sanofi
Merck
Astra Zeneca
-J&J
-Takeda
Eli Lilly
BI
-Novartis
-NN market share
-NN share of growth
1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione
2 CAGR for 5-year period; ; BI: Boehringer Ingelheim; J&J: Johnson & Johnson
Source: IQVIA MAT, Nov 2021 value figures Note: IQVIA data can be inflated due to use of list prices in the USView entire presentation